Emmaus Life Sciences, Inc. (EMMA) Research

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.

Market snapshot

Symbol
EMMA
Price
$0.01
Day change
-4.00%
Market cap
$673.8K
P/E ratio
-0.08x
52-week range
0.008-0.0175
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Bio-Path Holdings, Inc. (BPTH)
  • Helix BioMedix, Inc. (HXBM)
  • Nutra Pharma Corp. (NPHC)
  • NeutriSci International Inc. (NRXCF)
  • Orgenesis Inc. (ORGS)
  • Pure Harvest Corporate Group, Inc. (PHCG)
  • SQZ Biotechnologies Company (SQZB)
  • Vibe Growth Corporation (VIBEF)

Recent insider activity

  • DU HENRY HUY — trade (0 shares) on 2026-04-16
  • Kuwahara Jon — trade (0 shares) on 2024-10-01
  • Lim Seah H. — P-Purchase (20000 shares) on 2024-09-16
  • LEE WILLIS C — P-Purchase (77000 shares) on 2024-02-29
  • LEE WILLIS C — P-Purchase (15000 shares) on 2024-02-28

Open Emmaus Life Sciences, Inc. (EMMA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.